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Abstract
Introduction: Renal stones are common, with a lifetime prevalence of 10% in adults. Global incidence is increasing
due to increases in obesity and diabetes, with these patient populations being more likely to suffer renal stone
disease. Flank pain from stones (renal colic) is the most common cause of emergency admission to UK urology
departments. Stones most commonly develop in the lower pole of the kidney (in ~35% of cases) and here are least
likely to pass without intervention. Currently there are three technologies available within the UK National Health
Service to remove lower pole kidney stones: extracorporeal shockwave lithotripsy (ESWL), percutaneous
nephrolithotomy (PCNL) and flexible ureterorenoscopy (FURS) with laser lithotripsy. Current evidence indicates there
is uncertainty regarding the management of lower pole stones, and each treatment has advantages and
disadvantages. The aim of this trial is to determine the clinical and cost effectiveness of FURS compared with ESWL
or PCNL in the treatment of lower pole kidney stones.
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Methods: The PUrE (PCNL, FURS and ESWL for lower pole kidney stones) trial is a multi-centre, randomised
controlled trial (RCT) evaluating FURS versus ESWL or PCNL for lower pole kidney stones. Patients aged ≥16 years
with a stone(s) in the lower pole of either kidney confirmed by non-contrast computed tomography of the kidney,
ureter and bladder (CTKUB) and requiring treatment for a stone ≤10 mm will be randomised to receive FURS or
ESWL (RCT1), and those requiring treatment for a stone >10 mm to ≤25 mm will be randomised to receive FURS or
PCNL (RCT2). Participants will undergo follow-up by questionnaires every week up to 12 weeks post-intervention
and at 12 months post-randomisation. The primary clinical outcome is health status measured by the area under
the curve calculated from multiple measurements of the EuroQol five dimensions five-level version (EQ-5D-5L)
questionnaire up to 12 weeks post-intervention. The primary economic outcome is the incremental cost per quality-
adjusted life year gained at 12 months post-randomisation.
Discussion: The PUrE trial aims to provide robust evidence on health status, quality of life, clinical outcomes and
resource use to directly inform choice and National Health Service provision of the three treatment options.
Trial registration: ISRCTN: ISRCTN98970319. Registered on 11 November 2015.




Renal tract stone disease is very common, with a lifetime
prevalence of approximately 10% in the adult population
across the world [1]. It mainly affects adults of working
age and the incidence has been increasing over the past
decades [2, 3]. This increase is partly due to people with
obesity or diabetes being more likely to suffer renal
stone disease and results in a higher burden for health
care and associated costs for high-resource countries [4].
Approximately 50% of people with renal tract stones will
experience symptoms, typically kidney pain, and about
25% of patients with stones will require active treatment
[5–7]. Some people with stones can develop more ser-
ious problems including uncontrolled pain, infection,
visible blood in the urine (haematuria), impaired kidney
function and kidney failure. Despite successful removal
of the initial stone, any treated patients may develop a
further stone, with a lifetime recurrence risk of 50% [8].
Renal stones are a major burden on the National Health
Service (NHS) in the UK resulting in over 82,000 in-
patient hospital stays and over 25,000 procedures carried
out to remove stones in England in 2013–2014 [9]. Kid-
ney pain from stones (renal colic) is the most common
cause of emergency admission to urology departments
in the UK and, given the age group most commonly af-
fected, results in time off work and loss of economic ac-
tivity [3]. The ongoing need for pain killers and the
detriment to family, social and work activity reduces
quality of life and incurs additional costs.
Stones most commonly develop in the lower part (pole)
of the kidney, accounting for up to 35% of cases [10]. There
are currently three technologies available within the NHS
to remove lower pole kidney stones: extracorporeal shock-
wave lithotripsy (ESWL), percutaneous nephrolithotomy
(PCNL) and flexible ureterorenoscopy (FURS) with laser
lithotripsy. The choice of treatment can be guided by stone
size, likely stone composition, the anatomy of the drainage
system of the affected kidney, clinician and patient prefer-
ence, and availability of equipment and expertise [11].
Current evidence indicates that the success rate in terms of
stone clearance differs between these technologies, which
may partly be related to stone size. They are also distinct in
terms of the degree of invasiveness, anaesthetic require-
ment, treatment setting, number of procedures required to
clear the stone, and type and rate of complications [11, 12].
ESWL is non-invasive, has a low risk of complications,
and does not require anaesthesia. Current evidence sug-
gests it has reasonable efficacy in terms of stone clear-
ance for smaller lower pole stones at 3 months (63–74%
clearance rate for stones ≤10mm) [10]. However, 3-
month efficacy rates for lower pole stones >10 mm ap-
pear to be lower (23–56% for 11–20mm stones, and
14–33% for 21–30 mm stones) [13, 14]. If the stone is
not cleared then additional treatments may be required
using either repeated ESWL or more invasive options.
Following ESWL, small residual stone fragments can be
left in the kidney and may result in recurrent stone for-
mation over time (20% at 5 years) [7, 15].
Having considered this evidence, guidance issued by
the European Association of Urology and widely
followed in UK clinical practice recommends ESWL as
an option for lower pole stones ≤10mm, whereas for lar-
ger stones the recommended options are FURS or PCNL
[11]. However the guidance adds that ESWL may be
used for larger stones if stone factors and patient prefer-
ence are favourable. Flexible ureteroscopy and laser frag-
mentation and PCNL are more invasive than ESWL,
require a general anaesthetic, and carry a greater risk of
complications [16, 17]. A single FURS treatment appears
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to result in a good clearance rate for stones up to 15
mm, with repeat procedures or combined procedures re-
quired for larger stones. PCNL is the most invasive
treatment option and is associated with a higher risk of
complications, but it also appears to result in the highest
stone clearance rates which are close to 100% for stones
≤10mm, 93% for stones 11–20 mm and 86% for stones
21–30mm [18]. Stone clearance rates for FURS appear
to lie between those of ESWL and PCNL [19–25]. The
European Association of Urology guidance also com-
ments that there remains considerable uncertainty re-
garding the management of lower pole stones, with each
treatment option having advantages and disadvantages.
Rationale for the trial
A Cochrane review and meta-analysis in 2014 of rando-
mised controlled trials (RCTs) compared ESWL with ei-
ther FURS or PCNL for the treatment of renal stones
[12]. The review concluded that PCNL had a better
stone-free rate than ESWL at 3 months (relative risk
(RR) 0.39, 95% confidence interval (CI) 0.27–0.56),
whereas FURS appeared to have similar stone-free rates
to ESWL (RR 0.91, 95% CI 0.64–1.30). The meta-
analysis included five RCTs (n = 338); however, only
three focused on lower pole stones. Of these three RCTs
(160 participants), two compared ESWL with PCNL, one
for stones up to 30mm13 and one for stones up to 20
mm [26]. The third compared ESWL with FURS for
lower pole stones ≤10 mm [27]. The review concluded
that the included trials were small and of low methodo-
logical quality. The authors had planned to undertake
subgroup analyses by size and location of stone, but this
was not done “because of insufficient data”.
A systematic review performed by some of the PUrE
(PCNL, FURS and ESWL for lower pole kidney stones)
investigators [28] focused solely on stones located in the
lower pole of the kidney, and included trials comparing
PCNL with FURS (a comparison not considered in the
Cochrane review). This review identified four additional
relevant trials involving 408 participants [29–32] and we
undertook subgroup analyses by stone size (<10mm and
10–20mm). Looking at the seven trials involving partici-
pants with lower pole kidney stones as a whole, the
Grading of Recommendations Assessment, Development
and Evaluation certainty of evidence ratings for the out-
come of stone-free rates indicated they were of ‘moder-
ate’ quality. Our meta-analyses found PCNL and FURS
produced significantly higher stone-free rates than
ESWL for lower pole stones ≤20mm at 3 months. Com-
bining two RCTs (n = 155), stone-free rates for those
participants with stones ≤20mm were higher following
PCNL than ESWL (RR 2.04, 95% CI 1.50–2.77; Fig. 1).
Combining five RCTs (n = 508) showed that FURS re-
sulted in a higher stone clearance rate than ESWL (RR
1.31, 95% CI 1.08–1.59; Fig. 2). However, in a subgroup
meta-analysis combining three studies (n = 300) for
stones ≤10mm the advantage of FURS over ESWL was
less, although still statistically significant (RR 1.11,
95%CI 1.03–1.19; Fig. 2). One RCT (n = 93) which re-
ported the stone-free rate categorised by stone size for
PCNL versus ESWL found that the degree of superiority
of PCNL was lower for stones ≤10mm compared to
those >10 mm to ≤20mm (RR 1.56, 95% CI 1.11–2.21
versus RR 2.40, 95% CI 1.67–3.44; Fig. 2). Although
stone-free rates were higher when treated with PCNL
than with FURS, there was considerable uncertainty
around this estimate as the data came from only one
small RCT (n = 28) [30].
The included trials reported few data on patient out-
comes (such as quality of life) or on resource use, and
none on cost effectiveness. Pearle and colleagues [27]
suggested that ESWL gave better quality of life, shorter
convalescence (days to 100% recovered), and had fewer
analgesic requirements than FURS (participants had
lower pole stones ≤10mm). Conversely, Singh and col-
leagues [33] reported significantly higher participant sat-
isfaction with FURS and comparable convalescence
(time to return to routine activity) after having three or
fewer ESWL sessions (participants had stone sizes of
10–20mm). Convalescence was shorter after just a single
Fig. 1 Forest plot demonstrating the meta-analysis of percutaneous nephrolithotomy (PCNL) versus extracorporeal shockwave lithotripsy (ESWL)
for the outcome of stone-free rate at 3 months for lower pole stones ≤20mm. Albala and colleagues (2001) [13] and Yuruk and colleagues (2010)
[26] reported outcomes for lower pole stones <20 mm. Albala and colleagues [13] also reported outcomes for stones ≤10 mm and 11–20 mm
(see Table 1 in Donaldson and colleagues [28]). CI confidence interval, df degrees of freedom, M-H Mantel–Haenszel
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ESWL session. There were conflicting data on patients’
willingness to undergo the procedure again. In one trial
[27] the participants favoured ESWL, whereas in another
[33] FURS was preferred. ESWL (one session) was associ-
ated with a shorter hospital stay than either PCNL [13] or
FURS [27]. One trial also suggested shorter treatment dur-
ation for ESWL (one session) than FURS [27].
In summary, there is some evidence to inform esti-
mates of the relative clinical effectiveness (based on the
stone-free rate) of ESWL, FURS and PCNL in the treat-
ment of lower pole stones and to guide clinical practice,
but for most outcomes there is only moderate or low
certainty in the evidence [28]. There is sparse evidence
on the impact of these treatments on patient-reported
health status and quality of life outcomes (such as sever-
ity and duration of pain after intervention), their care
pathway (such as the need for additional treatments)
and resource use. The PUrE trial aims to provide robust
evidence on health status, quality of life, clinical out-
comes and resource use to both the NHS and society to
close this gap in evidence. The results will benefit
patients, clinicians and the NHS as it will inform
provision, guidance and decision-making in regard to
which of the competing interventions (ESWL, FURS or
PCNL) is the most suitable (clinically effective and cost
effective) for the treatment of people with lower pole
kidney stones of varying sizes.
Methods
Trial objectives
The aim of this study is to determine which of FURS,
PCNL and ESWL offers the best treatment outcomes in
terms of clinical effectiveness and cost effectiveness for
people with lower pole kidney stones seeking treatment
within the UK NHS. An initial pilot phase will be built
in to the trial to assess feasibility of recruitment and
check appropriateness of eligibility criteria and outcome
measures. The research question to be addressed is: in
people requiring treatment for lower pole stones of the
kidney does FURS with laser lithotripsy result in better
quality of life than standard treatment with ESWL or
Fig. 2 Forest plot demonstrating meta-analysis of flexible ureterorenoscopy (FURS) versus extracorporeal shockwave lithotripsy (ESWL) for the
outcome of stone-free rate for lower pole stones at 3 months. Sener and colleagues (2014) [32] and Pearle and colleagues (2005) [27] included
stones ≤10mm; Singh and colleagues (2014) [33] included stones 10–20 mm; Kumar and colleagues (2013) [29] and Salem and colleagues (2013)
[31] included stones ≤20 mm. Kumar and colleagues [29] reported results for stones 0–9.99 mm and 10–20 mm individually, whilst Salem and
colleagues [31] only reported results for stones ≤20 mm. All studies reported the stone-free rate at 3 months, except Singh and colleagues [33]
who reported the stone-free rate at 1 month. CI confidence interval, df degrees of freedom, M-H Mantel–Haenszel
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PCNL according to stone size, and is it cost-effective for
the UK NHS?
The clinical effectiveness and cost effectiveness of
FURS as the first treatment option in comparison to
ESWL for stones ≤10 mm in maximum dimension or
PCNL for stones >10 mm and ≤25mm in maximum di-
mension will be determined with respect to: 1) patient-
reported health status measured as area under the curve
(AUC) of the EuroQol five dimensions five-level version
(EQ-5D-5L) questionnaire completed at multiple time
points up to 12 weeks post-intervention; 2) incremen-
tal cost per quality-adjusted life year (QALY) at 12
months post-randomisation; 3) successful stone clear-
ance at 12 weeks; 4) further interventions required to
treat stones within 12 months of randomisation; and
5) treatment-related harms experienced up to 12
months after randomisation.
The null hypotheses being tested are: 1) the use of
FURS to treat lower pole kidney stones ≤10 mm will not
be different to ESWL as assessed by the EQ-5D-5L AUC
up to 12 weeks post-treatment; 2) the use of FURS to
treat lower pole stones of the kidney >10 mm and ≤25
mm will not be different to PCNL as assessed by the
EQ-5D-5L AUC up to 12 weeks post-treatment.
Trial design
The trial will comprise two separate (RCT1 and RCT2)
pragmatic, multi-centre, patient-randomised, open-label
superiority RCTs with an initial internal pilot phase. A
summary of the trial design is shown in Fig. 3. RCT1 will
compare FURS with ESWL, recruiting patients with
stones of maximum dimension ≤10 mm. RCT2 will com-
pare FURS with PCNL, recruiting patients with stones of
maximum dimension >10mm and ≤25mm.
Interventions to be evaluated
The experimental intervention FURS will be compared
with the standard interventions ESWL and PCNL. All
three interventions are currently in general use by ur-
ology departments throughout the UK NHS. This trial
aims to test the interventions in a standard NHS setting
so that the results are generalisable to current routine
care in the UK. In line with this aim, all procedures will
be delivered in NHS facilities and supervised by NHS
staff trained and competent in the procedures. All par-
ticipants will be under the care of a named consultant
urologist who, as in standard NHS practice, will be re-
sponsible for planning and carrying out the allocated
procedure and arranging follow-up. The surgical inter-
ventions FURS and PCNL will be carried out by a
trained urologist, or by a trainee urologist under the
supervision of a senior urologist. They will be supported
by the standard team of ward and theatre staff and
radiographers. In some centres, a specialist uro-
radiologist will also assist with the procedures, particu-
larly with access to the stone. The ESWL intervention
can be delivered using any device approved for this pur-
pose including both fixed-site and mobile lithotriptors.
Delivery of the treatment will be according to local prac-
tice by staff trained in the procedure, typically a radiog-
rapher and nurse, and supervised by a urologist. The
techniques and equipment used for FURS, PCNL and
ESWL continue to evolve and hence will differ in detail
between different surgeons and departments. The trial
protocol will not mandate the use of any specific de-
tailed technical method for each intervention, but as part
of trial initiation of each site the standard procedure in-
cluding equipment used for FURS, PCNL and ESWL for
that site will be recorded on a trial proforma and up-
dated with changes as necessary. It is anticipated that at
8–12 weeks post-intervention participants will receive
imaging to assess stone clearance in accordance with
usual standard of care.
For FURS, a thin (3-mm diameter) flexible endoscope
(ureteroscope) is passed into the kidney via the natural
urinary passages (urethra, bladder and ureter) and is
used to directly see the stone. A laser fibre (typically 200
or 273 μm holmium laser fibre) is then passed through
the working channel of the ureteroscope and laser en-
ergy used to fragment the stone within the kidney. Lar-
ger fragments can be retrieved with a wire basket device
passed through the working channel whilst smaller frag-
ments (<2 mm) may be left to pass spontaneously. Gen-
erally, the patient will pass remaining fragments in the
urine during the week following the procedure. The pro-
cedure is performed as a day-case or with an overnight
stay (2014 NHS average = 1.7 days) and usually requires
general anaesthesia. A single dose of antibiotic to pre-
vent infection is often given at the start of the procedure.
The duration of the operation depends on size of stone
but is typically 1.0–1.5 h. A temporary ureteral stent
may be placed at the end of the procedure to protect
against blockage of the ureter caused by swelling of its
lining cells. The operating surgeon will monitor progress
and degree of stone clearance during the procedure and
this may be checked with a plain kidney x-ray after-
wards. Possible harms of the procedure are urinary tract
infection, bleeding and damage to the urinary system
which may require a more prolonged period of stenting.
The stent itself can cause pain and urinary symptoms
such as increased urinary frequency and haematuria. For
the purposes of the PUrE trial, FURS treatment is ex-
pected to be a single procedure in the great majority of
cases. However, an additional procedure will be consid-
ered as part of the FURS treatment strategy in cases of
technical complexity or larger stones as long as it takes
place with 6 weeks of the initial FURS procedure. Any
additional procedures will be recorded separately for
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trial purposes. Once stone clearance has been confirmed
the ureteric stent will be removed as an outpatient pro-
cedure with local anaesthetic. Placement and removal of
the stent will be considered part of the FURS treatment
strategy in the PUrE trial.
ESWL involves the generation of an external acoustic
(sound) pulse, called a shockwave, outside the body
which is then focused onto the kidney stone through the
patient’s flank skin, causing it to fragment. Stone frag-
ments pass down the urinary tract spontaneously which
may take a few weeks. It is routinely performed in an
outpatient setting with analgesia, with or without sed-
ation as required. A single dose of antibiotic may be
given at the start of the procedure if there is thought to
be a higher than normal risk of getting an infection
afterwards. Each session lasts 1.0–1.5 h and stone frag-
mentation is monitored during the procedure and then
by a plain x-ray (or other imaging as standard) taken at
a follow-up appointment at approximately 3 weeks. For
the PUrE trial, two separate ESWL treatments will be
considered as part of the initial ESWL intervention strat-
egy. These should take place within an 8-week period
and each episode will be recorded separately for trial
purposes. The treating urologist may, however, decide
that further ESWL is not appropriate if stone fragmenta-
tion is insufficient following the first or second session.
Fig. 3 The clinical and cost effectiveness of interventions for stones in the lower pole of the kidney: the percutaneous nephrolithotomy (PCNL),
flexible ureterorenoscopy (FURS) and extracorporeal shockwave lithotripsy (ESWL) for lower pole kidney stones randomised controlled trial (PUrE
RCT). EQ-5D-5L EuroQol five dimensions five-level version questionnaire, NRS Numeric Rating Scale, SF-12 12-item short-form survey
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The first session of ESWL will be taken as the initial
treatment point for the purposes of timing of outcome
assessments. Possible harms of ESWL include urinary
tract infection, visible bleeding in the urine and blockage
of the ureter by the stone fragments. There is also a
small risk of bruising surrounding the kidney.
PCNL is a surgical procedure to remove stones from
the kidney by a direct approach. A small (10-mm) inci-
sion is made on the skin overlying the kidney through
which a needle is passed into the urine collecting tube
system of the kidney. This can be guided either by sim-
ultaneous ultrasound imaging of the kidney or by pre-
liminary telescopic placement of a tube through the
urethra, bladder and ureter. Contrast fluid can then be
injected into the collecting system to guide the needle
passage through the skin and into the kidney. Placement
of the needle is planned using the available imaging (typ-
ically a computed tomography scan of the kidneys, ure-
ters and bladder (CTKUB)) to give the best access to
successfully remove the stone. For a stone in the lower
pole of the kidney placement is usually into the lower-
most part of the collecting system. Once the needle is
satisfactorily placed, a flexible guide wire is then passed
into the collecting system of the kidney and used to
guide stretching (dilatation) of the needle track to make
it wide enough for a hollow rigid access sheath to be
passed creating a 10-mm wide channel between the
skin and the urine collecting system of the kidney. A
rigid metal telescope (nephroscope) can then be
inserted down this channel into the kidney’s collect-
ing system to see the stone and either retrieve it
whole using graspers or to fragment the stone using a
variety of energy delivery devices, most commonly an
ultrasonic probe or pneumatic device. After the oper-
ation, the kidney is drained for a period by a tube
placed either through the access channel or as a stent
down the ureter into the bladder. In addition, a urin-
ary catheter may be inserted to drain the bladder for
a short period after the procedure. The operation is
performed under general anaesthesia with a typical
duration of 1–3 h depending on complexity, and pa-
tients usually stay in hospital for a few days (2014
NHS average stay = 4.6 days). Antibiotic treatment is
frequently given at the start of the procedure and
may be continued for a few days after if there is ac-
tive infection. The drainage tubes are usually removed
after 24–48 h without the need for further anaesthesia.
Stone clearance is monitored during the procedure and, if
necessary, by a plain x-ray (or other imaging) before dis-
charge from hospital. Possible harms include urinary in-
fection, bleeding (which may be severe), and inadvertent
puncture of other organs. For the PUrE trial, a single
PCNL treatment is expected to be required to completely
remove stones up to 25mm.
Apart from randomised allocation of the initial inter-
vention and participant completion of questionnaires,
the PUrE trial does not seek to change or impose any
specific protocol regarding the clinical management of
participants recruited at each trial site. The trial will
however record relevant aspects of participant care dur-
ing their involvement in the trial up to 12months after
randomisation and obtain patient-reported outcome
measures. In particular, trial participants undergoing any
of the stone treatments under test may require further
interventions either to correct harms arising from the
initial intervention or because of inadequate stone clear-
ance by the initial intervention. The circumstances, na-
ture and outcome of these additional procedures will be
recorded, and patient -reported outcome measures ob-
tained where possible before and after each additional
intervention to assess the effect on health status.
Trial population
The trial population will consist of adults (≥16 years old)
presenting to NHS urology departments with a stone
≤25mm in the lower pole of the kidney confirmed by
non-contrast CTKUB. The patient and clinician must
agree that active intervention is appropriate to remove
the lower pole stone, and patients must be able to
undergo either treatment for the specific stone size and
be capable of giving informed consent which includes
adherence with the requirement of the trial. Patients
with multiple stones will be eligible provided all stones
in the lower pole measure ≤25 mm in maximum dimen-
sion and, if there are stones of any size elsewhere in the
urinary system, that the lower pole stone is the priority
for treatment. A list of study sites is available on the
study website (www.puretrial.org).
Selection of participants
Clinicians will assess patients presenting with lower pole
kidney stone. This will be aided by patient and clinician
trial publicity material. A screening log documenting
brief details of potentially eligible patients but without
personal identifiers will be kept at each site to provide a
summary of reasons for non-inclusion in the study to in-
form the Consolidated Standards of Reporting Trials
diagram and assess generalisability of trial findings.
Planned inclusion and exclusion criteria
Inclusion criteria
 Adults ≥16 years of age
 Lower pole stone ≤25 mm in maximum dimension
with the decision to treat that stone
 Presence of stone previously confirmed by CTKUB
 Able and willing to undergo either treatment for the
specified stone size
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 Capacity to give informed consent to participate in




 Patients with a co-existing stone that takes prece-
dence in deciding treatment modality (such as an
obstructing ureteric stone or large upper pole stone)
 Patients with health or other factors that are
absolute contraindications to an intervention that
they may be allocated
 Patients unable to understand or complete trial
documentation
Recruitment and trial procedures
Identifying participants
Patients with lower pole stones eligible for PUrE may be
referred electively to urology departments having had a
stone identified opportunistically by abdominal imaging
or during investigation of urinary tract symptoms. Alter-
natively, they may present as an emergency with loin
pain or infection. We will therefore inform clinical teams
at each trial site of the target population backed up by
trial publicity and trial summaries. At an appropriate
point during their initial assessment, patients will be in-
formed about the trial and given or sent information
about the trial including a patient information leaflet
with the contact details of the local research team. Pa-
tients will be given adequate time to consider participat-
ing in the study. They will have the opportunity to take
study information away with them if desired, in which
case the local research team will contact the patient after
at least 24 h to determine their interest. If the patient is
interested, the research team will confirm eligibility and
discuss the individual’s possible participation with the
clinical team. If both patient and clinical team agree re-
garding participation, arrangements will be made for
consent to study, randomisation and clinical discussion
and timing of allocated treatment. Wherever possible
these processes will be arranged to take place together
during one visit. Patients who decline, those who are in-
eligible or those for whom one of the possible allocated
treatments is unsuitable will be recorded without identi-
fiers on a screening log.
Informed consent
The patient information leaflet explains that the trial is
investigating the effectiveness of active interventions for
stones in the lower pole of the kidney. Patients will be
informed that, depending on stone size, the trial will in-
vestigate whether the use of FURS will be superior to
ESWL (stones ≤10mm) or to PCNL (stones >10 mm
and ≤25mm). Signed informed consent forms will be ob-
tained from the participants in all centres. Participants
who cannot give informed consent (e.g. due to incap-
acity) will be not be eligible for participation. The
participant’s permission will be sought to inform their
general practitioner that they are taking part in this
trial. We will also take optional consent for agree-
ment to be approached for further studies on kidney
stones, and for long-term follow-up through their
local and central NHS clinical records after their ac-
tive trial participation has finished.
Randomisation and allocation
Eligible and consenting participants, who have previ-
ously had a CTKUB to confirm the presence and size of
stone, will be randomised dependent on the stone size
using the telephone interactive voice response random-
isation application or via the web-based application —
both hosted by the fully registered UK Clinical Research
Collaboration Clinical Trials Unit at the Centre for
Healthcare Randomised Trials (CHaRT) Health Services
Research Unit in Aberdeen, UK. Participants with a
stone ≤10mm will be entered into RCT1 and rando-
mised to either FURS or ESWL. Participants with a
stone >10 mm and ≤25mm will be entered into RCT2
and randomised to either FURS or PCNL. Participants
will then follow the standard care pathway for the allocated
treatment. All the treatments allocated by randomisation in
the study are used in routine clinical practice and in this
pragmatic trial patients are expected to be treated using
normal local clinical pathways and guidelines. The only
trial-specific interventions apart from randomised treat-
ment allocation will be participant completion of outcome
questionnaires. Adherence to the allocated intervention will
be monitored by the trial office team.
Blinding
There can be no blinding of participants, clinical staff or
the central trial team to the allocated trial arm due to
the differing nature of the interventions.
Follow-up procedures
Eligible patients who have given signed informed con-
sent to participate in the study will be asked to complete
the EQ-5D-5L, 12-item short-form survey (SF-12), pain
score (by the Numeric Rating Scale (NRS)) and use of
analgesic questions at baseline prior to randomisation. A
baseline clinical case report form (CRF) will also be
completed that will include stone size measured as the
maximum dimension on a CTKUB. They will then be
randomised to either one of the interventions dependent
on the size of the lower pole stone and placed upon the
appropriate waiting list. Waiting time duration for the
trial interventions will be recorded and monitored.
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Participants will be asked to complete the pain score
(NRS), EQ-5D-5L and use of analgesic questions at a
number of fixed and variable time points during their
trial participation. Fixed points will be baseline, just
prior to initial intervention, weekly up to 12 weeks after
initial intervention (FURS, PCNL and first ESWL ses-
sion) and at 12 months post-randomisation. Variable
points after 12 weeks will be just prior and 1 week after
any additional intervention (including planned additional
sessions of ESWL and removal of stent) and during any
other hospital admissions related to treatment of their
lower pole kidney stone (such as admissions for pain
control or infection). At 12 weeks following the initial
intervention, and at 12 months post-randomisation, par-
ticipants will be asked to complete questions relating to
their primary and secondary care use and their associ-
ated travel. At 12 months post-randomisation partici-
pants will be asked to additionally complete the SF-12.
Participants will also be given the opportunity to
complete an EQ-5D-5L at their discretion throughout
the duration of the trial. A subset of 100 participants will
receive the Cambridge Renal Stone Patient Reported
Outcome Measure [34], a disease-specific health-related
quality of life tool, at baseline, pre-intervention and at
12 weeks post-intervention.
Reminders may be used; for the earlier time points
this may be a text message or email on the day that
the questionnaire is due and, for the later time points
(e.g. 12 weeks and 12 months), this reminder will be
sent approximately 2 weeks and 4 weeks after the
questionnaire is due.
We will offer and use all methods of delivery and col-
lection of questionnaires and reminders including use of
research teams for time points associated with hospital-
isation, postal mail, email, web-based, telephone and
SMS text, taking into account each participant’s stated
preferred means of receiving and completing the mea-
sures. Participants will be sent a voucher (of modest
value) as a token of appreciation for completion and re-
turn of the questionnaires.
CRFs collecting information on received care process
and outcome will be completed by site research teams at
baseline, following each initial and subsequent additional
intervention (including planned additional ESWL ses-
sions and stent removal), at 12 weeks post-intervention,
after any additional stone-related treatments (e.g. admis-
sions due to pain or infection) and 12months post-
randomisation. These will be entered at site into the
web-based trial management platform.
To measure the secondary clinical outcome of stone
clearance, participants will have kidney imaging at be-
tween 8 and 12 weeks according to clinical need and
participant convenience. We will state preference for im-
aging by CTKUB during site initiation, but renal
ultrasound and plain x-ray will be acceptable according
to patient preference, safety and local practice. We will
ask local site clinical teams (radiologist/urologist) to
state whether there is: complete clearance of the target
stone from the urinary tract defined as no further action
or observation required for that stone; acceptable clear-
ance where observation is required but no intervention
planned; and unacceptable clearance where further
intervention will be required. The maximum dimension
of the largest remaining fragment in millimetres will also
be recorded.
Withdrawal procedures
Participants are free to withdraw consent to participate
at any time. Outcome data derived from medical records
will be collected for those that withdraw unless the par-
ticipant specifically withdraws their consent for this. All
data collected up to the point of withdrawal will be
retained and used in the analysis. Failure to undergo al-
located treatment either because of participant prefer-
ence or change of circumstance will not result in
withdrawal and the participant will continue to partici-
pate in trial procedures unless consent to the trial is
withdrawn.
End of trial
The end of participation in the trial for each participant
is defined as the final data capture to answer the re-
search question: the 12-month post-randomisation ques-
tionnaire and CRF or the 12-week post-intervention
questionnaire and CRF, whichever comes last.
Safety
The PUrE trial involves procedures for treating lower
pole stones that are all well established in current NHS
clinical practice. Adverse effects may occur during or
after any type of surgery. We will monitor serious ad-
verse events and the local Principal Investigator or their
delegate at the site will categorise these as expected or
unexpected. Only serious unexpected adverse events re-
lated to the trial interventions or death of a participant
will be notified to the Sponsor and Ethics Committee.
Hospital visits (planned or unplanned) associated with
further interventions or complications of treatment (e.g.
expected adverse events) due to the lower pole stone will
be recorded as an outcome measure but will not be re-
ported as serious adverse events. Other serious adverse
events related to the intervention will not be reported a
serious adverse event, but will be recorded in the CRFs.
Planned primary care or hospital visits for conditions
other than those associated with the lower pole stone
will not be collected or reported. All deaths for any
cause (related or otherwise) will be recorded on the ser-
ious adverse event form.
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Within PUrE, ‘related’ is defined as an event that oc-
curs as a result of a procedure required by the protocol,
whether or not it is either the specific intervention allo-
cated at randomisation or administered as an additional
intervention as part of normal care.
Provisions for post-trial care
Standard care is provided within the UK NHS.
Outcome measures
Primary outcome measure
The primary outcome measures are health status mea-
sured by EQ-5D-5L AUC to 12 weeks post-intervention,
based upon EQ-5D-5L completion at fixed time points
(at baseline (recruitment), just prior to initial interven-
tion (FURS, PCNL or first session of ESWL), weekly up
to 12 weeks after initial intervention) and at variable
time points (just prior to any additional intervention (in-
cluding planned additional ESWL sessions and removal
of stent) and once during hospitalisation for adverse
events related to treatment (e.g. pain and infection)),
and incremental cost per QALY gained at 12 months
post-randomisation based on the estimated NHS costs
and participant responses to the EQ-5D-5L (including
an additional time point at 12 months).
Secondary outcome measures
Secondary outcome measures include the severity of
pain as measured by the NRS (completed with EQ-5D-
5L), generic health profile as measured by the SF-12
(completed at baseline and 12months), use of analgesics
(completed with NRS and EQ-5D). In addition,
secondary outcome measures include stone clearance
measured between 8 and 12 weeks following the initial
intervention using renal imaging (CTKUB preferred, but
plain x-ray and ultrasound are also acceptable), the max-
imum dimension of the largest fragment of the treated
stone in millimetres, the need for additional treatment
(carried out or planned) at 12 weeks post-initial treat-
ment and 12months post-randomisation, complications
during the initial intervention, and intervention-related
complications at 12 weeks (categorised by Clavien–
Dindo classification) following treatment and up to 12
months post-randomisation. All these will be measured
by site staff and entered on the CRF.
We will also record NHS primary and secondary care
resources used and their costs, patient costs (out of
pocket expenses), and time off work up to 12months
post-randomisation. Data gathered from completion of
CRFs by site staff and participant questionnaire at 12
weeks following initial treatment and 12months post-
randomisation will also be recorded.
Data collection and processing
Measuring outcomes
Outcome data will be collected throughout the trial for
each participant from consent until 12 months following
randomisation. See Table 1 for the schedule of events.
Data processing
Data collected locally will be input at sites by the local
research team. Staff in the trial office will work closely
with the local research teams to ensure data are as
complete and accurate as possible. Participant
Table 1 Source and timing of measures
Timing
Intervention (PCNL or first session ESWL/FURS)
Weeks post intervention Additional intervention





Outcome measure Source Baselinea Pre 1 to 11 12
Health status EQ-5D-5L PQ ✓ ✓ ✓ ✓ ✓ ✓
Pain PQ ✓ ✓ ✓ ✓ ✓ ✓
Health profile SF12 PQ ✓ ✓ ✓ ✓
Use of analgesics PQ ✓ ✓ ✓ ✓ ✓ ✓
Stone clearance (imaging) CRF ✓b ✓
Additional interventions received CRF&PQ ✓ ✓ ✓
Complications CRF&PQ ✓ ✓ ✓
NHS primary and secondary healthcare use CRF, PQ ✓ ✓ ✓ ✓
Participant costs PQ ✓ ✓ ✓
CRF case report form, PQ participant completed questionnaire
aBaseline is after informed consent has been given but prior to randomisation
bstone imaging performed at 8-12 weeks post treatment
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questionnaires will be sent from and returned to the trial
office in Aberdeen with the exception of the 1- and 2-
week questionnaires, which may be distributed by the
local research teams. Extensive range and consistency
checks will further enhance the quality of the data.
Confidentiality
Data are stored in accordance with Good Clinical
Practice and with the UK Data Protection Acts 1998
and 2018.
Sample size, proposed recruitment rate and milestones
Sample size
The primary outcome is the AUC measured from mul-
tiple completions of the EQ-5D-5L by each participant
up to 3 months following initial intervention (FURS,
PCNL or first session of ESWL). In order to detect a
standard deviation difference of 0.3, with 90% power,
and alpha set at 5%, 235 participants per group (470 in
total) are required. Such a difference in generic health
status is considered clinically relevant and, in terms of
treatment effect size, in the small to medium range as
observed in other clinical studies. To allow for the antic-
ipated 10% of participants for whom outcome data will
be completely missing, and therefore the AUC cannot be
calculated, it is proposed to randomise 522 participants
in both RCT1 and RCT2, giving a total trial population
of 1044 participants.
Recruitment rates
We plan to recruit the trial population from approxi-
mately 50 NHS centres across the UK, each recruiting
an average of one participant per month to either RCT1
or RCT2. Our plan is to achieve the target of 1044 par-
ticipants (522 to each RCT) over a 52-month recruit-
ment window.
Statistical analysis
The primary outcome — health status AUC — will be
generated for each participant using the trapezoidal rule.
Data for participants who have missed a scheduled time
point will be estimated using a multiple imputation ap-
proach to make use of partial outcome data. Sensitivity
analyses will be conducted to assess the robustness of
the treatment effect estimate to these approaches. The
primary outcome measure will be analysed using linear
regression with adjustment for design variables. Second-
ary outcomes will be analysed using generalised linear
models with adjustment for design and baseline variables
as appropriate. Subgroup analyses will explore the pos-
sible modification of treatment effect by important fac-
tors (centre, participant body mass index, stone size
(maximum dimension and volume), stone density on
CTKUB (Hounsfield units), skin to stone distance). We
will also explore within each allocated group whether
technical factors modify the treatment effect (access
sheath versus no access sheath and digital versus non-
digital instrument (FURS); fixed-site versus mobile de-
vice (ESWL); calibre of access track (PCNL)). This will
be done by including treatment-by-factor interactions in
the model and they will be classified as exploratory ana-
lyses. All analyses will initially be performed on an
intention-to-treat basis, although we will consider add-
itional analysis groups such as per-protocol if indicated.
The main statistical analyses will be based on all partici-
pants as randomised, irrespective of subsequent compli-
ance with the treatment allocation. All treatment effects
sizes will be summarised by estimates and 95% CIs from
the appropriate models. From the feasibility phase we
will report estimates of recruitment rates and potential
participant availability, together with appropriate CIs.
There are no planned interim outcome analyses; all ana-
lyses will occur following completion of trial follow-up.
Interim analyses will be performed if requested by the
Data Monitoring Committee (DMC).
All analyses will follow a carefully documented statis-
tical analysis plan. RCT1 and RCT2 will be analysed en-
tirely separately. The Trial Steering Committee (TSC)
and the independent DMC will be asked to review and
comment on the statistical analysis plan prior to analysis.
We propose that progress and monitoring of the two
RCTs will be undertaken within the same DMC and
TSC. The team propose that each study will be analysed
once completed. The DMC and TSC will meet before
recruitment begins to agree its terms of reference and
other procedures.
Economic evaluation
An economic evaluation to assess the relative efficiency of
trial care pathways will be an integral part of the study. A
within -trial analysis [35, 36] as well as a simple Markov
model [37, 38] to extrapolate the analysis beyond the RCT
follow-up period will be considered. The perspective of
the analysis will be that of the NHS and personal social
services [39]. The analysis will rely on participant re-
sponses to the EQ-5D-5L to estimate quality-adjusted life
years (QALYs) at 12months. Resource use and costs will
be estimated for each participant. The evaluation will con-
sider the costs of the care pathways that patients receive.
This will include costs of the interventions (ESWL, FURS,
and PCNL) and the cost of simultaneous and consequent
use of primary and secondary NHS services (including
additional interventions received) by participants. Personal
costs such as purchase of medications, particularly analge-
sics, will be estimated. As the clinical condition commonly
affects people of working age, time off work will be also
recorded to estimate indirect costs (e.g. human capital ap-
proach). The incorporation of indirect costs into the
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economic evaluation is debatable; however, the collection
of these data will open the possibility to include these
costs into the analysis or report them separately following
reporting practice at the time of analysis.
Participant-level resource use data will be captured for
the initial intervention and any subsequent admissions/
treatments required through to 12months post-
randomisation using CRFs. Patient primary care services
resource use as well as medications will be recorded
using a patient questionnaire delivered at 12 weeks post-
intervention and at 12 months post-randomisation. Spe-
cial attention will be taken on questionnaire wording to
minimise recall time overlapping (and hence avoid
double counting). In addition, the patient questionnaires
will collect data on time off work. Each resource use
event will be valued using appropriate unit prices ob-
tained from national sources, including NHS reference
costs [40], and the unit cost of health and social care
[41]. The British National Formulary [42] will be used to
obtain unit costs to value medications, and published
wage categories used to value time off work. Total NHS
costs will be summed for each patient to 12months
post-randomisation.
Participant costs
Participant costs will comprise self-purchased health
care (e.g. prescription and over the counter medication).
Information will be collected using the 12-week post-
intervention and 12-month post-randomisation ques-
tionnaires. Participants will be asked for information on
travel costs incurred by visits to their general practi-
tioner, hospital doctor or other health care provider.
NHS resource use
The use of secondary care services following the treat-
ment period will be collected using participant question-
naires and CRFs. Information on outpatient visits
(participant questionnaire at 12 weeks post-intervention
and 12months post-randomisation), readmissions and
additional interventions relating to the use and conse-
quences of the interventions being compared will be re-
corded on the CRF. The use of primary care services
such as prescription medications, contacts with primary
care practitioners (e.g. general practitioners and practice
nurses) will be collected via the ‘health care utilisation
questions’ administered at 12 weeks post-intervention
and 12months post-randomisation.
Cost effectiveness
Cost effectiveness will be measured in terms of costs of
the treatment care pathways and QALYs at 12 months
post-randomisation for the within-trial analysis. Mean
NHS costs, patient costs and QALYs will be compared
between randomised groups at 12 months. Incremental
costs and QALYs will be estimated for FURS versus
ESWL (for participants with stones ≤10mm) and for
FURS versus PCNL (for participants with stones >10
mm and ≤25mm stones) using linear regression with ad-
justment for design variables and baseline values as ap-
propriate. The final decision on what regression model
to use is data-dependent. However, as the RCT is
planned to involve 50 recruitment sites from the UK the
use of multi-level regression models will be considered
[43]. Uncertainty surrounding joint estimates of incre-
mental cost and effects will be characterised and pre-
sented graphically using cost-effectiveness acceptability
curves [44, 45]. Guidelines for economic evaluation ad-
vocate for a long enough time horizon to consider all
cost and consequences relevant for the analysis [39]. In
order to assess longer term cost effectiveness, a simple
Markov model will be developed using available data on
recurrence rates and extrapolation of costs and effects
out to 5 years post-randomisation.
Trial management and oversight arrangements
The trial office is in the CHaRT based within the Health
Services Research Unit, University of Aberdeen, and pro-
vides day-to-day support for the local recruitment sites.
The PUrE trial office team aims to meet formally at least
monthly during the course of the trial to ensure smooth
running and trouble-shooting.
Project Management Group
The trial is supervised by its Project Management Group
consisting of the grant holders and representatives from
the trial office. The Project Management Group aim to
meet in person or by teleconference every 6 months on
average.
Trial Steering Committee
The trial is overseen by a TSC. The TSC comprises four
independent members, N. Parr (Chair), L. Harper, T.
Everitt and J. Hussey. CHaRT has adopted the TSC
charter adapted from the DAMOCLES charter for
DMCs and suggests to the independent TSC members
that they adopt the terms of reference contained within.
The TSC will meet approximately yearly.
Data Monitoring Committee
An independent DMC will be convened. The DMC is
comprised of three independent members, S. Payne
(chair), D. Douglas and R. Hills. The trial statistician
contributes as appropriate and the Chief Investigator
and/or a nominated delegate may contribute to the open
session of the meetings as appropriate. CHaRT has
adopted the DAMOCLES charter for DMCs and sug-
gests to the independent DMC members that they adopt
the terms of reference contained within.
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The Committee meets regularly to monitor the un-
blinded trial data and serious adverse events and to
make recommendations as to any modifications that are
required to be made to the protocol or the termination
of all or part of the trial.
Dissemination
All RCTs conducted by CHaRT have a commitment to
publish the findings of the research. At a minimum, this
trial will have a results paper published in a peer-
reviewed medical or scientific journal. If all grant holders
and research staff fulfil authorship rules, group author-
ship may be appropriate for some publications under the
collective title of ‘the PUrE Trial Group’. If one or more
individuals have made a significant contribution above
and beyond other group members, but where all group
members fulfil authorship rules, authorship may be at-
tributed to the named individual(s) and the PUrE Trial
Group.
To safeguard the integrity of the main trial, reports of
explanatory or satellite studies will not be submitted for
publication without prior arrangement from the Project
Management Group.
We intend to maintain interest in the trial by publica-
tion of PUrE newsletters at intervals for staff and collab-
orators. Once the main report has been published, a lay
summary of the findings will be sent in a final PUrE
newsletter to all involved in the trial, including trial
participants.
Discussion
The PUrE trial is a large, multi-centre, pragmatic RCT
to determine the clinical and cost effectiveness of surgi-
cal interventions for stones in the lower pole of the kid-
ney. The primary outcome for the study is participant-
reported health status (AUC up to 12 weeks post-
intervention calculated from multiple measurements of
the EQ-5D-5L).
It is not possible to blind the participants or clinicians
in PUrE due to the differing nature of the interventions
(invasive versus non-invasive) and their requirements
(e.g. anaesthesia, multiple treatments). This may be a
source of bias in the trial; however, this is limited by the
pragmatic nature of the study, randomisation and con-
cealment of allocation.
The main practical challenge of the study has been
participant recruitment. Stone disease has a high recur-
rence rate [1], and many of those approached will have
had a lived experience of treatment and this may influ-
ence their willingness to be randomised. Screening data
indicates that, of those approached, 30% of patients in
RCT1 have a preference for treatment that prevented
them from entering the trial, and this figure is higher in
RCT2 (41%). A qualitative study was instigated to
investigate this further to try and identify some best
practises from key sites to disseminate to all researchers.
However, we have experienced some difficulties imple-
menting the study, largely due to staff feeling uncom-
fortable about recruitment consultations being audio-
recorded.
Due to the unexpected issues with recruitment, trial
timelines have been extended by 18months to allow us
to reach the target for RCT1. Early on in the study it be-
came apparent that RCT2 would not recruit to target as
the patient population is not as large for RCT2 (stones
>10 and ≤25 mm) as it is for RCT1. This is reflected in
the screening data; there have been considerably fewer
patients screened for RCT2 compared to RCT1 (252 ver-
sus 1036 at the time of writing).
Other than the difficulties previously discussed there
have been no major issues conducting the PUrE study.
Trial status
The first participant was recruited in May 2016 and the
trial is currently open to recruitment in 50 UK centres. The
current protocol version is version 02, 2 September 2019.
Recruitment is due to complete on 30 September 2020.
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